Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 104 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2014', provides an overview of the Vancomycin-Resistant Enterococcus Faecium Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus Faecium Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Vancomycin-Resistant Enterococcus Faecium Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Vancomycin-Resistant Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vancomycin-Resistant Enterococcus Faecium Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus Faecium Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Vancomycin-Resistant Enterococcus Faecium Infections Overview 9
Therapeutics Development 10
Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections - Overview 10
Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections - Comparative Analysis 11
Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics under Development by Companies 12
Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics under Investigation by Universities/Institutes 15
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Vancomycin-Resistant Enterococcus Faecium Infections - Products under Development by Companies 18
Vancomycin-Resistant Enterococcus Faecium Infections - Products under Investigation by Universities/Institutes 19
Vancomycin-Resistant Enterococcus Faecium Infections - Companies Involved in Therapeutics Development 20
Piramal Enterprises Limited 20
Aphios Corporation 21
Wockhardt Limited 22
Alchemia Limited 23
Immtech Pharmaceuticals, Inc. 24
Lorus Therapeutics Inc. 25
NovaBay Pharmaceuticals, Inc. 26
Oragenics, Inc. 27
Microbio Co., Ltd. 28
MicuRx Pharmaceuticals, Inc. 29
Enanta Pharmaceuticals, Inc. 30
Cellceutix Corporation 31
TAXIS Pharmaceuticals, Inc. 32
LegoChem Biosciences, Inc 33
MGB Biopharma Limited 34
Sentinella Pharmaceuticals, Inc. 35
Sealife PHARMA GMBH 36
Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
MRX-I - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
LCB-010371 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
LOR-220 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
brilacidin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules for Bacterial Infections - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
MU-1140 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AVX-13616 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
PM-181104 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Marinus - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
WCK-4086 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecule for Bacterial Infections - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
SLP-0905 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MGB-BP-3 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Second Generation Oxas - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
NAI-107 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
EDP-788 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
IBN-1 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Epimerox - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
HT-02 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
auriclosene - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules for Gram Possitive Bacterial Infections - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Closthioamide - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
7-O-Malonyl Macrolactin A - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MB-225 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Chrysophaentin Antibiotics - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Vancomycin-Resistant Enterococcus Faecium Infections - Recent Pipeline Updates 79
Vancomycin-Resistant Enterococcus Faecium Infections - Dormant Projects 93
Vancomycin-Resistant Enterococcus Faecium Infections - Discontinued Products 94
Vancomycin-Resistant Enterococcus Faecium Infections - Product Development Milestones 95
Featured News & Press Releases 95
Oct 02, 2013: Cubist Presents Data On Tedizolid at IDWeek 2013 95
Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013 95
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project 97
Apr 26, 2013: Cempra To Present Data On Solithromycin's Potential Against Urogenital Infections And Multidrug-Resistant Pathogens At ECCMID 98
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140 99
Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-chlorotaurine And NVC-422 On Bacterial Toxins 99
Aug 14, 2012: Lorus Therapeutics Announces Issuance Of Patent In Japan For Antimicrobial Drug LOR-220 100
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 100
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 101
Mar 27, 2012: Lorus Therapeutics Announces Positive Results From Small Molecule Antimicrobial Program 101
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 104
Disclaimer 104

List of Tables
Number of Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections, H2 2014 10
Number of Products under Development for Vancomycin-Resistant Enterococcus Faecium Infections - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Development by Companies, H2 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Piramal Enterprises Limited, H2 2014 20
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Aphios Corporation, H2 2014 21
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Wockhardt Limited, H2 2014 22
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Alchemia Limited, H2 2014 23
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Immtech Pharmaceuticals, Inc., H2 2014 24
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Lorus Therapeutics Inc., H2 2014 25
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2014 26
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Oragenics, Inc., H2 2014 27
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Microbio Co., Ltd., H2 2014 28
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2014 29
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Enanta Pharmaceuticals, Inc., H2 2014 30
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Cellceutix Corporation, H2 2014 31
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H2 2014 32
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by LegoChem Biosciences, Inc, H2 2014 33
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by MGB Biopharma Limited, H2 2014 34
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H2 2014 35
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline by Sealife PHARMA GMBH, H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Number of Products by Stage and Target, H2 2014 39
Number of Products by Stage and Mechanism of Action, H2 2014 42
Number of Products by Stage and Route of Administration, H2 2014 44
Number of Products by Stage and Molecule Type, H2 2014 46
Vancomycin-Resistant Enterococcus Faecium Infections Therapeutics - Recent Pipeline Updates, H2 2014 79
Vancomycin-Resistant Enterococcus Faecium Infections - Dormant Projects, H2 2014 93
Vancomycin-Resistant Enterococcus Faecium Infections - Discontinued Products, H2 2014 94